Alzinova AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALZ.ST research report →
Companywww.alzinova.com
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.
- CEO
- Tord Labuda
- IPO
- 2015
- Employees
- 5
- HQ
- Mölndal, SE
Price Chart
Valuation
- Market Cap
- $51.32M
- P/E
- -1.99
- P/S
- 0.00
- P/B
- 0.36
- EV/EBITDA
- -1.65
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -19.89%
- ROIC
- -16.50%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-26,266,000 · -27.80%
- EPS
- $-0.26 · 16.13%
- Op Income
- $-25,853,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $2.28
- 52W Low
- $0.38
- 50D MA
- $0.55
- 200D MA
- $1.02
- Beta
- 0.76
- Avg Volume
- 884.68K
Get TickerSpark's AI analysis on ALZ.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ALZ.ST Coverage
We haven't published any research on ALZ.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALZ.ST Report →